Followers
0
Following
0
Blog Posts
0
Threads
78
Blogs
Threads
Portfolio
Follower
Following
2020-08-16 15:48 | Report Abuse
KUALA LUMPUR (Aug 10): Shares in Ho Wah Genting Bhd (HWGB) jumped 15.83% or 19 sen to RM1.39 in morning trade today after the group said last week that its subsidiary had inked a memorandum of understanding (MoU) to undertake phase-four clinical trials for a poliomyelitis vaccine for Covid-19.
At 10.50am, shares in HWGB were 11.67% or 14 sen higher at RM1.34, valuing the group at RM696.99 million. It saw 47.69 million shares traded, exceeding its 200-day average volume of 7.5 million shares.
According to the group’s filing with Bursa Malaysia last Thursday, its unit HWGB Biotech Sdn Bhd had partnered with US-based E-MO Biology Inc (EBI) for HWGB to invest a sum of US$1 million (RM4.2 million) in EBI, entitling it to 40% of profit from the commercialised vaccine.
HWGB said it will have exclusive rights for the production, distribution and sale of the repurposed vaccine based on the polio vaccine for use in preventing Covid-19 infections in Southeast Asian countries.
“EBI on June 15 submitted the Initial Investigational New Drug application to the United States Food and Drug Administration to conduct phase IV clinical trials for a new indication which proposes the use of the existing poliomyelitis virus vaccine for prevention of Covid-19, which is currently pending approval.
HWGB said the memorandum is not expected to have any immediate material effect on its earnings, net assets, gearing and share capital.
“However, the proposed collaboration is expected to contribute positively to earnings of HWGB upon successful commercialisation of the new indication.
“The board, having taken into consideration all aspects of the memorandum, is of the opinion that the memorandum is in the best interests of the company,” said HWGB
2020-08-16 15:45 | Report Abuse
40% of total net profit ...Joint venture
2020-08-16 15:44 | Report Abuse
Ho Wah Genting Bhd (HWGB) today signed a joint venture agreement (JV) with US-based E-Mo Biology Inc (EBI) to undertake Phase 4 clinical trials for a new poliomyelitis virus vaccine (PVV) for Covid-19.
The deal, which signed by HWGB's wholly-owned subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech), will also allow the latter to conduct research and development (R&D) of vaccines, immunological treatment and diagnostic product development for the Covid-19 virus.
Under the JV, HWGB Biotech will invest US$1 million and be entitled to a 40 per cent of the total net profit, HWGB Bursa Malaysia filing today said.
Furthermore, following the memorandum of agreement signed on 06 August 2020, HWGB Biotech will also be entitled to exclusive rights for the production, distribution and the sale of the Covid-19 vaccine in Southeast Asia countries.
"We hope the repurposing of the proven poliovirus vaccines can fast track the Covid-19 vaccine development to save lives, as the situation now is dire," said HWGB chief executive officer Datuk Aaron Lim Ooi Hong.
"Additionally, the JV represents a further step to firm up the collaboration of both parties that will be beneficial for both," he said in the exchange filing.
EBI will carry out the R&D, testing, registration and commercialisation of the 5 provisional patent application and other activities relating to the patents which EBI owns, for the purpose of treating the diseases.
The vaccine is currently awaiting necessary approval from the United States Food and Drug Administration (FDA) to conduct Phase 4 clinical trials.
2020-08-16 15:41 | Report Abuse
Catch when price low, and sell when price higher... don't not matter ...how it works
2020-08-16 15:31 | Report Abuse
Littlefish90 same with me... If paper loss, this counter still give dividend or not
2020-08-16 14:08 | Report Abuse
This counter climax already?? Hopefully can climax for 2nd time...at 0.05
2020-08-15 15:58 | Report Abuse
What I see in all comment in klse group stock , the negatives comment but soon price flying to sky...but prise higher to sky for some stock, price jumping to earth after that...
2020-08-14 22:14 | Report Abuse
Standby ... coming flying again soon
https://www.nst.com.my/business/2020/08/616633/ho-wah-genting-inks-jv-deal-us-firm-develop-distribute-covid-19-vaccine
2020-08-14 00:34 | Report Abuse
Most other countries chasing to create vaccine
2020-08-13 13:09 | Report Abuse
Believe can reach 0.05 -0.06. still hold
2020-08-13 00:28 | Report Abuse
This one after share consolidate price can propit or not...
2020-08-13 00:25 | Report Abuse
I believe can reach 0.035 - 0.04 next next week
2020-08-12 20:24 | Report Abuse
I bought at price 0.38 last week...still hold even berdarah...lawan
2020-08-11 23:17 | Report Abuse
Really good for long investment...never sell for this moment..hold 0.025
2020-08-11 23:13 | Report Abuse
Shark still hold tight this counter... Follow the flow
2020-08-11 23:08 | Report Abuse
To stable profit oil take more time year to year... So gold is better investment
2020-08-11 23:06 | Report Abuse
Emas dengan minyak. Prefer emas lagi. Harga minyak bole drop negative jika ekonomj prob...emas takkan punyalah... Lg satu ..org minyak dah manyak rugi ma...klu Naik pun sekejap masa berita vasin keluar...
2020-08-11 23:00 | Report Abuse
This counter like XOX..feel regret no buy at 0.075 XOX...now price XOX too high.. Now hold 0.065 for DGB . waiting to reach...0.2..hold tigh
2020-08-11 17:25 | Report Abuse
Minggu ni x cantik , tp bole grab harga murah lg, next akan ada news gold Mahal lg...Naik mencanak balik...xkn tggu news baru beli, jual bila keluar news la, skrg beli
2020-08-11 17:23 | Report Abuse
Harga manyak diskaun skrg ma, beli..next going up..higher...
Stock: [HWGB]: HO WAH GENTING BHD
2020-08-16 15:50 | Report Abuse
KUALA LUMPUR: Ho Wah Genting Bhd (HWGB) today signed a joint venture agreement (JV) with US-based E-Mo Biology Inc (EBI) to undertake Phase 4 clinical trials for a new poliomyelitis virus vaccine (PVV) for Covid-19.
The deal, which signed by HWGB's wholly-owned subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech), will also allow the latter to conduct research and development (R&D) of vaccines, immunological treatment and diagnostic product development for the Covid-19 virus.
Under the JV, HWGB Biotech will invest US$1 million and be entitled to a 40 per cent of the total net profit, HWGB Bursa Malaysia filing today said.
Furthermore, following the memorandum of agreement signed on 06 August 2020, HWGB Biotech will also be entitled to exclusive rights for the production, distribution and the sale of the Covid-19 vaccine in Southeast Asia countries.
"We hope the repurposing of the proven poliovirus vaccines can fast track the Covid-19 vaccine development to save lives, as the situation now is dire," said HWGB chief executive officer Datuk Aaron Lim Ooi Hong.
"Additionally, the JV represents a further step to firm up the collaboration of both parties that will be beneficial for both," he said in the exchange filing.
EBI will carry out the R&D, testing, registration and commercialisation of the 5 provisional patent application and other activities relating to the patents which EBI owns, for the purpose of treating the diseases.
The vaccine is currently awaiting necessary approval from the United States Food and Drug Administration (FDA) to conduct Phase 4 clinical trials.